SVF
Level D· Preclinical EvidenceLaboratory Study

Novel Combination Scalp Therapy for Androgenetic Alopecia: A Preliminary Retrospective Case Series with an Illustrative Four-Year Case.

Lee JH., Hahn HM.

Laboratory Study with a reported sample of 6 on Hair Loss, Hair Regeneration, published in J Clin Med (2026) — summary generated from the PubMed abstract.

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Laboratory Study
Journal
J Clin Med (2026)
Country
Switzerland
Reported sample size
6
PMID
42452517
DOI
10.3390/jcm15135055

Abstract (original English)

Background/Objectives : Androgenetic alopecia (AGA) responds only partially to pharmacologic monotherapy. Combination procedural regimens incorporating platelet-rich plasma (PRP), stromal vascular fraction (SVF), and botulinum toxin (BTX) have been reported, but objective quantitative trichoscopic data on multimodal single-session protocols are limited. We retrospectively quantified the trichoscopic response to a four-component single-session scalp procedure used in routine clinical practice. Methods : Fifty-one consecutive AGA patients underwent a single-session procedure combining partial temporalis muscle resection with silicone implantation, negative-pressure scalp stimulation, and BTX, PRP, and SVF injections; 28 completed ≥ 4-month follow-up. Standardized 60× videodermoscopy at five predefined scalp locations was archived for paired quantitative analysis in six patients (30 location pairs, of which 28 were analyzable after excluding two pairs for motion artifact), with one additional patient imaged at four years. Six trichoscopic outcomes were derived by automated image analysis (Otsu thresholding, skeletonization, distance-transform shaft thickness); the primary analysis was performed at the patient level ( n = 6) and a supporting analysis at the panel level ( n = 28), each using paired Student's t -tests. Results : In the primary patient-level analysis ( n = 6 patients)

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence comes from animal or laboratory studies and has not been confirmed in humans.

How we grade evidence
Hair & ScalpHair LossHair Regeneration
View on PubMedDOI

Related research